

OFFICIAL

FAX RECEIVED

JUN 15 1999

GROUP 1600

MCGREGOR & ADLER, LLP

P.O. BOX 710509
HOUSTON, TEXAS 77271-0509WRITER'S DIRECT DIAL
(713)-777-2321
WRITER'S DIRECT FACS.
(713)-777-6908
E. MAIL: BAADLER@flash.netINTELLECTUAL PROPERTY LAW
(PATENT, BIOTECHNOLOGY, COMPUTER,
TRADEMARK & TRADE SECRET LAW)June 15, 1999

FACSIMILE COVER SHEET

PLEASE DELIVER TO: EXAMINER G.E. BUGAISKYCOMPANY: Patent and Trademark OfficeFACSIMILE NUMBER: (703) 308-4242NUMBER OF PAGES (COUNTING COVER SHEET): 7FROM: Benjamin A. AdlerMESSAGE: Please deliver the attached to Examiner Bugaisky. Examiner Bugaisky, enclosed please find the Response to the 5/17/99 Office Action for 08/915,659 (D6020). Thank you.

CONFIDENTIALITY NOTICE: Unless otherwise indicated or obvious from the nature of this transmittal, the information contained in this facsimile is attorney privileged and confidential information intended for the use of the individual or entity named above. If the reader is not the intended recipient or an employee or agent responsible for delivery, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you receive this communication in error, please immediately notify Dr. Benjamin A. Adler at (713) 777-2321 and promptly return the facsimile. Thank you.

RECEIVED

JUN 15 1999

GROUP 1800

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: T. O'Brien *et al.*

§ ART UNIT: 1653

FILED: August 21, 1997

§
§
§
§
§
§
§

EXAMINER:

SERIAL NO.: 08/915,659

G. E. Bugaisky

FOR: Novel Extracellular Serine Protease

DOCKET: D6020


The Assistant Commissioner of Patents and Trademarks
Box AF
Washington, DC 20231

Certificate of Facsimile Transmission

I certify that this response was transmitted via Facsimile to
Examiner G. E. Bugaisky at the Patent Office on the date indicated below.

15 June 1999

Date


Benjamin Aaron Adler, Ph.D., J.D.RESPONSE UNDER 37 CFR 1.116

Dear Sir:

Responsive to the Final Office Action mailed May 17,
1999, please enter the following amendments. Reconsideration of
this application as amended is respectfully requested.

IN THE CLAIMS:

Please amend claim 1 as follows:

1. (twice amended) DNA encoding a Tumor Antigen
Derived Gene-14 (TADG-14) protein, wherein said protein has [shares
at least 95% sequence identity with] the amino acid sequence shown